Back to Search Start Over

Comparison between laparoscopic and abdominal radical hysterectomy for stage IB1 and tumor size <2 cm cervical cancer with visible or invisible tumors: a multicentre retrospective study.

Authors :
Pengfei Li
Lan Chen
Yan Ni
Jiaqi Liu
Donglin Li
Jianxin Guo
Zhihua Liu
Shuangling Jin
Yan Xu
Zhiqiang Li
Lu Wang
Xiaonong Bin
Jinghe Lang
Ping Liu
Chunlin Chen
Source :
Journal of Gynecologic Oncology; Mar2021, Vol. 32 Issue 2, p1-13, 13p
Publication Year :
2021

Abstract

Objective: To compare 5-year disease-free survival (DFS) and overall survival (OS) rates of laparoscopic radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) for stage IB1 and tumor size &lt;2 cm with visible or invisible tumors. Methods: We retrospectively compared the oncological outcomes of 1,484 cervical cancer patients with IB1 and tumor size &lt;2 cm on final pathology, who received ARH (n=899) or LRH (n=585) between January 2004 and December 2016. Patients were divided into visible tumor subgroup (ARH: n=668, LRH: n=444) and invisible tumor subgroup (ARH: n=231, LRH: n=141) according to tumor type. Results: LRH and ARH showed similar 5-year DFS and OS rates (93.3% vs. 93.1%, p=0.997; 96.2% vs. 97.5%, p=0.351) in total study population. LRH was not associated with worse 5-year DFS rate (hazard ratio [HR]=0.96; 95% confidence interval [CI]=0.58-1.58; p=0.871) or OS rate (HR=1.37; 95% CI=0.65-2.89; p=0.409) by multivariable analysis. In the visible tumor subgroups, LRH and ARH showed similar 5-year DFS and OS rates (91.9% vs. 91.9%, p=0.933; 95.0% vs. 96.9%, p=0.276), and LRH was not associated with worse 5-year DFS or OS rate (p=0.804, p=0.324). In the invisible tumor subgroups, LRH and ARH also showed similar 5-year DFS and OS rates (97.3% vs. 97.1%, p=0.815; 100% vs. 99.5%, p=0.449), and LRH was not associated with worse 5-year DFS rate (p=0.723). Conclusions: Among patients with stage IB1 and tumor size &lt;2 cm, whether the tumor is visible or not, the oncological outcomes of LRH and ARH among cervical cancer patients are comparable. This suggests that LRH may be suitable for stage IB1 and tumor size &lt;2 cm with visible or invisible tumors. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20050380
Volume :
32
Issue :
2
Database :
Complementary Index
Journal :
Journal of Gynecologic Oncology
Publication Type :
Academic Journal
Accession number :
149213178
Full Text :
https://doi.org/10.3802/jgo.2021.32.e17